Cardio Diagnostics Holdings (CDIO) Total Liabilities (2021 - 2026)
Cardio Diagnostics Holdings (CDIO) posted Total Liabilities of $655972.0 for Q1 2026, down 17.29% sequentially from $793061.0 in Q4 2025, and down 27.52% YoY from $904998.0 in Q1 2025.
Cardio Diagnostics Holdings (CDIO) Total Liabilities (2021 - 2026) Analysis & Trends
Cardio Diagnostics Holdings has reported Total Liabilities for 6 years, with the latest figure at $655972.0 in Q1 2026.
- Quarterly Total Liabilities fell 27.52% year-over-year to $655972.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $655972.0 (down 27.52% YoY) and the FY2025 annual result came in at $793061.0, down 25.01% from the prior year.
- Total Liabilities fell to $655972.0 in Q1 2026 per CDIO's latest filing, from $793061.0 in the prior quarter.
- Over five years, Total Liabilities peaked at $5.1 million in Q1 2023 and troughed at $180542.0 in Q1 2022.
- A 5-year average of $1.5 million and a median of $904998.0 in 2025 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2024: Total Liabilities soared 5648.18% in 2022, then slumped 78.36% in 2024.
- Over 5 years, Total Liabilities stood at $1.9 million in 2022, then decreased by 22.77% to $1.5 million in 2023, then declined by 29.7% to $1.1 million in 2024, then slipped by 25.01% to $793061.0 in 2025, then dropped by 17.29% to $655972.0 in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $655972.0, $793061.0, and $637331.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 10.03 Bn |
| 10 | Cardio Diagnostics Holdings | 6.03 Mn | 443,812.80 | - | 499,780.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 499,780.00 |
| Mar 31, 2026 | 655,972.00 |
| Dec 31, 2025 | 793,061.00 |
| Sep 30, 2025 | 637,331.00 |
| Jun 30, 2025 | 671,848.00 |
| Mar 31, 2025 | 904,998.00 |
| Dec 31, 2024 | 1.06 Mn |
| Sep 30, 2024 | 795,276.00 |
| Jun 30, 2024 | 922,529.00 |
| Mar 31, 2024 | 1.29 Mn |
| Dec 31, 2023 | 1.50 Mn |
| Sep 30, 2023 | 3.68 Mn |
| Jun 30, 2023 | 3.85 Mn |
| Mar 31, 2023 | 5.13 Mn |
| Dec 31, 2022 | 1.95 Mn |
| Sep 30, 2022 | 631,748.00 |
| Jun 30, 2022 | 229,434.00 |
| Mar 31, 2022 | 180,542.00 |
| Dec 31, 2021 | 33,885.00 |